PMID- 11981350
OWN - NLM
STAT- MEDLINE
DCOM- 20020906
LR  - 20221207
IS  - 0268-1315 (Print)
IS  - 0268-1315 (Linking)
VI  - 17
IP  - 3
DP  - 2002 May
TI  - Treatment of generalized anxiety disorder with citalopram.
PG  - 103-7
AB  - Serotonin reuptake inhibitors (SSRI), such as venalafaxine and paroxetine, are 
      used in the treatment of generalized anxiety disorder (GAD). Patients with GAD 
      frequently have comorbid psychiatric disorders, such as depression. SSRIs are 
      effective in the treatment of a variety of anxiety disorders and depression. 
      Citalopram, a newer SSRI used in the treatment of depression, has not been 
      studied for GAD. This is the first report of the use of citalopram, the most 
      selective SSRI, for the treatment of GAD in a retrospective case observation 
      study. Thirteen patients diagnosed with GAD were treated with citalopram at an 
      academic outpatient clinic. The main outcome measures were the Hamilton Rating 
      Scale for Anxiety (HAM-A), Hamilton Depression Rating Scale (HAM-D) and Clinical 
      Global Impressions of Severity (CGI-S; at baseline) and Improvement (CGI-I). The 
      mean age of the patients was 38 years. The mean dose of citalopram at endpoint 
      was 33 mg/day (range 10-60 mg/day). After 12 weeks of treatment with citalopram, 
      all 13 patients experienced full or partial improvement in GAD and depressive 
      symptoms leading to meaningful improvement in social and occupational 
      functioning. Mean baseline HAM-A scores (mean+/-SEM) decreased from 22.2+/-1.3 to 
      6.2+/-0.9 after citalopram treatment. The mean CGI-I score was 1.8+/-0.2 with 11 
      of the 13 patients responding (CGI-I of 1 or 2). These data suggest that 
      citalopram may be an effective treatment for GAD. Several patients who had failed 
      previous treatment with other SSRIs responded to citalopram, suggesting that a 
      second SSRI, such as citalopram, may be beneficial in this population. A larger 
      placebo-controlled study of citalopram is warranted in GAD.
FAU - Varia, I
AU  - Varia I
AD  - Department of Psychiatry and behavioural Sciences, Duke University Medical 
      Center, Durham, NC 27710, USA. varia001@mc.duke.edu
FAU - Rauscher, F
AU  - Rauscher F
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Int Clin Psychopharmacol
JT  - International clinical psychopharmacology
JID - 8609061
RN  - 0 (Serotonin Uptake Inhibitors)
RN  - 0DHU5B8D6V (Citalopram)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anxiety Disorders/*drug therapy
MH  - Citalopram/*pharmacology
MH  - Depression
MH  - Drug Resistance
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Selective Serotonin Reuptake Inhibitors/*pharmacology
MH  - Severity of Illness Index
MH  - Treatment Outcome
EDAT- 2002/05/01 10:00
MHDA- 2002/09/07 10:01
CRDT- 2002/05/01 10:00
PHST- 2002/05/01 10:00 [pubmed]
PHST- 2002/09/07 10:01 [medline]
PHST- 2002/05/01 10:00 [entrez]
AID - 10.1097/00004850-200205000-00002 [doi]
PST - ppublish
SO  - Int Clin Psychopharmacol. 2002 May;17(3):103-7. doi: 
      10.1097/00004850-200205000-00002.